Biogenity

Hjem
Danmark
Aalborg
Biogenity

Biogenity is a data-driven biotechnology company.

02/09/2026

📄 𝗣𝘂𝗯𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝘀𝗽𝗼𝘁𝗹𝗶𝗴𝗵𝘁: 𝗧𝗮𝗿𝗴𝗲𝘁𝗲𝗱 𝗽𝗿𝗼𝘁𝗲𝗼𝗺𝗶𝗰𝘀 𝘀𝘂𝗽𝗽𝗼𝗿𝘁𝗶𝗻𝗴 𝗞𝗹𝗼𝘁𝗵𝗼 𝗿𝗲𝘀𝗲𝗮𝗿𝗰𝗵 (𝟮𝟬𝟮𝟭)
In 2021, a study published in Scientific Reports investigated expression of the longevity-associated protein α-Klotho in the naked mole rat, a species known for its exceptional lifespan.

Because no specific antibodies exist for detecting Klotho in this model, the researchers applied targeted proteomics using Parallel Reaction Monitoring (PRM) to measure Klotho protein expression in kidney and liver tissue.

At Biogenity, we performed the PRM-based proteomics analysis, using high-resolution mass spectrometry to detect Klotho-derived peptides in complex tissue samples.

We enjoy looking back at studies like this, where targeted mass spectrometry enables protein-level measurements when conventional approaches are not available.

🔗 https://doi.org/10.1038/s41598-021-94972-1

01/09/2026

📚 𝗛𝗼𝘄 𝗮 𝗰𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝗼𝗯𝘀𝗲𝗿𝘃𝗮𝘁𝗶𝗼𝗻 𝗯𝗲𝗰𝗮𝗺𝗲 𝗕𝗶𝗼𝗴𝗲𝗻𝗶𝘁𝘆
What started as an observation at a research conference in Dublin has grown into a company working with clients worldwide.

Our co-founder and CEO, Kenneth Kastaniegaard, first saw the opportunity while completing his PhD: a huge amount of existing research data was going underused, while researchers kept running costly new experiments to get answers that were often already there. That insight became the foundation for Biogenity.

Aalborg University recently featured our story - from the early idea to how we work today, helping researchers, hospitals, and biotech and pharma companies turn biological data into insights that move their research forward.

𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗳𝘂𝗹𝗹 𝗮𝗿𝘁𝗶𝗰𝗹𝗲 𝗵𝗲𝗿𝗲: https://www.aau.dk/a-remark-in-dublin-sowed-the-seed-for-biogenity-n172399

23/08/2026

💬 𝗔 𝗾𝘂𝗲𝘀𝘁𝗶𝗼𝗻 𝘄𝗲 𝗼𝗳𝘁𝗲𝗻 𝗴𝗲𝘁 𝗮𝘁 𝗕𝗶𝗼𝗴𝗲𝗻𝗶𝘁𝘆
“𝘊𝘢𝘯 𝘺𝘰𝘶 𝘩𝘢𝘯𝘥𝘭𝘦 𝘥𝘪𝘧𝘧𝘪𝘤𝘶𝘭𝘵 𝘰𝘳 𝘶𝘯𝘶𝘴𝘶𝘢𝘭 𝘴𝘢𝘮𝘱𝘭𝘦 𝘵𝘺𝘱𝘦𝘴?”

Often, yes - but feasibility is always assessed case by case.

We work with a wide range of sample types, including human and animal material (blood, tissue, biopsies), microbial cultures, secretomes, plant material, and both model and non-model organisms.

Challenging samples often benefit from early discussion, as preparation, handling, and analytical choices can make a significant difference. Reviewing this upfront helps avoid surprises and ensures the data you receive is meaningful and usable.

👉 𝘞𝘢𝘯𝘵 𝘺𝘰𝘶𝘳 𝘲𝘶𝘦𝘴𝘵𝘪𝘰𝘯 𝘧𝘦𝘢𝘵𝘶𝘳𝘦𝘥 𝘪𝘯 𝘢𝘯 𝘶𝘱𝘤𝘰𝘮𝘪𝘯𝘨 𝘘&𝘈 𝘦𝘱𝘪𝘴𝘰𝘥𝘦? 𝘈𝘥𝘥 𝘪𝘵 𝘵𝘰 𝘵𝘩𝘦 𝘤𝘰𝘮𝘮𝘦𝘯𝘵𝘴.

18/08/2026

🧬 𝐇𝐢𝐠𝐡-𝐒𝐞𝐧𝐬𝐢𝐭𝐢𝐯𝐢𝐭𝐲 𝐏𝐫𝐨𝐭𝐞𝐨𝐦𝐢𝐜𝐬 𝐟𝐨𝐫 𝐋𝐨𝐰-𝐈𝐧𝐩𝐮𝐭 𝐄𝐕 𝐒𝐚𝐦𝐩𝐥𝐞𝐬
Extracellular vesicle samples are frequently limited in yield, which can constrain standard proteomics workflows.

At Biogenity, DIA-MS workflows optimised for low-input EV samples typically yield 1,000 to 2,500 proteins per sample, supporting both discovery proteomics and targeted quantification, with PTM workflows available, including phosphorylation.

💬 Working with low-input EV samples? Let's discuss whether this workflow fits your project.

🔗 https://biogenity.com/extracellular-vesicles

13/08/2026

🗺️ 𝐌𝐚𝐩𝐩𝐢𝐧𝐠 𝐒𝐲𝐬𝐭𝐞𝐦 𝐁𝐢𝐨𝐥𝐨𝐠𝐲 𝐓𝐡𝐫𝐨𝐮𝐠𝐡 𝐌𝐮𝐥𝐭𝐢𝐨𝐦𝐢𝐜𝐬
Many research questions extend beyond what a single omics layer can explain, particularly when investigating mechanisms rather than a single biomarker.

At Biogenity, multiomics integration combines proteomics, transcriptomics, metabolomics, and lipidomics within a single study, providing a more complete view of system-level biological processes.

💬 Considering a multiomics approach for your next study? Let's discuss your integration strategy.

🔗 https://biogenity.com/multi-omics

11/08/2026

𝗙𝗿𝗼𝗺 𝗦𝗮𝗺𝗽𝗹𝗲 𝘁𝗼 𝗕𝗶𝗼𝗹𝗼𝗴𝗶𝗰𝗮𝗹 𝗜𝗻𝘀𝗶𝗴𝗵𝘁 🧬
A clear, structured process matters as much as analytical quality when choosing a research partner.

At Biogenity, projects follow a guided path: consultation, tailored sample preparation, sample analysis matched to the project's sensitivity, statistical and bioinformatic data analysis, timely delivery, and a post-consultation discussion to walk through the results together.

💬 Planning a project and want to understand how the process works end-to-end? 𝗟𝗲𝘁'𝘀 𝘁𝗮𝗹𝗸, 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝘀𝘁 𝘁𝗼 𝘀𝗰𝗶𝗲𝗻𝘁𝗶𝘀𝘁

🔗 https://biogenity.com

05/08/2026

📄 𝗣𝘂𝗯𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻 𝘀𝗽𝗼𝘁𝗹𝗶𝗴𝗵𝘁: 𝗠𝘂𝗹𝘁𝗶𝗼𝗺𝗶𝗰𝘀 𝗶𝗻𝘀𝗶𝗴𝗵𝘁𝘀 𝗶𝗻𝘁𝗼 𝗼𝗯𝗲𝘀𝗶𝘁𝘆, 𝗹𝘂𝗻𝗴 𝗿𝗲𝗺𝗼𝗱𝗲𝗹𝗶𝗻𝗴, 𝗮𝗻𝗱 𝗮𝗴𝗶𝗻𝗴
In a 2025 study published in Cell Reports, researchers used a comprehensive multiomics strategy to investigate how obesity reshapes the lung microenvironment.

By combining advanced proteomics, ECM-focused analyses, scRNA-seq, and functional assays, the study shows that obesity drives profound matrisome remodeling, altered elastic fiber organization, and fibroblast activation - changes that partially overlap with hallmarks of lung aging.

At Biogenity, we contributed by performing mass-spectrometry-based proteomics and data analysis, including ECM and BALF proteomics workflows. These datasets helped uncover solubility shifts, matrisome remodeling, and protease–inhibitor imbalance in the obese lung.

We enjoy looking back at studies like this, where advanced proteomics enables deeper understanding of tissue remodeling, mechanics, and disease-relevant biology.

🔗 𝗥𝗲𝗮𝗱 𝘁𝗵𝗲 𝗽𝘂𝗯𝗹𝗶𝗰𝗮𝘁𝗶𝗼𝗻: https://www.cell.com/cell-reports/fulltext/S2211-1247(25)01056-3

04/08/2026

🧬 𝗢𝗹𝗶𝗻𝗸 𝗣𝗿𝗼𝘁𝗲𝗼𝗺𝗶𝗰𝘀 𝗶𝗻 𝗺𝘂𝗹𝘁𝗶-𝗼𝗺𝗶𝗰𝘀 𝗶𝗻𝘁𝗲𝗴𝗿𝗮𝘁𝗶𝗼𝗻
Proteins represent the functional layer of many biological processes. When integrated with genomics, transcriptomics, metabolomics, or clinical data, proteomics enables deeper biological interpretation.

At Biogenity, Olink proteomics is frequently deployed as part of multi-omics strategies, supporting systems-level insights into disease mechanisms, treatment response, and patient stratification.

𝗥𝘂𝗻𝗻𝗶𝗻𝗴 𝗮 𝗺𝘂𝗹𝘁𝗶-𝗼𝗺𝗶𝗰𝘀 𝘀𝘁𝘂𝗱𝘆? Reach out to discuss how Olink proteomics can complement your existing data layers.

🔗 https://biogenity.com/olink-proteomics

30/07/2026

✨ 𝗖𝗼𝗺𝗯𝗶𝗻𝗲𝗱 𝗺𝗲𝘁𝗮𝗯𝗼𝗹𝗼𝗺𝗶𝗰𝘀 𝗽𝗮𝗻𝗲𝗹𝘀 𝗶𝗻 𝘀𝘆𝘀𝘁𝗲𝗺𝘀-𝗹𝗲𝘃𝗲𝗹 𝗺𝗲𝘁𝗮𝗯𝗼𝗹𝗶𝘀𝗺
Single metabolomics panels are rarely enough when the biological question spans multiple pathways. Energy metabolism, lipid regulation, micronutrients, and microbiome-linked metabolites are tightly connected, and analyzing them in isolation often limits interpretation.

Biogenity’s combined metabolomics panels are designed for studies that need a broader biochemical context. By combining complementary targeted panels with an integrated untargeted screen, we enable pathway-level interpretation while retaining quantitative precision.

This approach is particularly useful when the goal is to understand how multiple metabolic processes change together, rather than focusing on a single pathway.

If your research question spans multiple metabolic pathways, let’s discuss whether a combined panel approach makes sense.

🔗 https://biogenity.com/metabolomics/combined-metabolomics-panels

Adresse

Niels Jerns Vej 10
Aalborg
9220

Hvad er åbningstiderne?

Mandag	09:00 - 16:00
Tirsdag	09:00 - 16:00
Onsdag	09:00 - 16:00
Torsdag	09:00 - 16:00
Fredag	09:00 - 16:00

Internet side

https://biogenity.com/

Underretninger

Vær den første til at vide, og lad os sende dig en email, når Biogenity sender nyheder og tilbud. Din e-mail-adresse vil ikke blive brugt til andre formål, og du kan til enhver tid afmelde dig.

Vil du plassere din virksomhed på toppen av Forretning-listen i Aalborg?